Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11599928 | 0.80 | CYP1A2 (0.49) | CYP1A2 | |
| SCHEMBL13439132 | 0.80 | KCNH3 (0.33) | KCNH3CYP1A2 | |
| SCHEMBL11380065 | 0.80 | KCNH3 (0.33) | KCNH3CYP1A2 | |
| SCHEMBL18557973 | 0.80 | KCNH3 (0.33) | KCNH3CYP1A2 | |
| SCHEMBL7909133 | 0.80 | KCNH3 (0.33) | KCNH3CYP1A2 | |
| SCHEMBL10158346 | 0.80 | KCNH3 (0.33) | KCNH3CYP1A2 | |
| SCHEMBL21311743 | 0.79 | FAAH (0.43) | KCNH3CYP1A2 | |
| SCHEMBL16115353 | 0.79 | — | — | |
| SCHEMBL1759484 | 0.78 | CYP1A2 (0.56) | CYP1A2 | |
| SCHEMBL4502053 | 0.78 | CYP1A2 (0.36) | KCNH3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553842-B2 | Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases | ARRAY BIOPHARMA INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1838316-A2 | MACROCYCLIC ANALOGS FOR THE TREATMENT OF IMMUNOREGULATORY DISORDERS AND RESPIRATORY DISEASES | Array Biopharma, Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006078724-A2 | MACROCYCLIC ANALOGS FOR THE TREATMENT OF IMMUNOREGULATORY DISORDERS AND RESPIRATORY DISEASES | ARRAY BIOPHARMA NC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160838-A1 | Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases | ARRAY BIOPHARMA INC. | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160838-A1 | Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases | TSLP, XDH, IFNG | KCNH3 3861/4885CYP1A2 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.